
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Importance of Biomarkers for Lung Cancer
Author(s)Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Advertisement
Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Articles in this issue
over 11 years ago
The Implementation of Personalized Medicine for Lung Cancer Patientsover 11 years ago
The Benefit of Treating Lung Cancer with Immunotherapyover 11 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCover 11 years ago
In Practice: Systemic Treatment for Metastatic NSCLCover 11 years ago
Clinical Trial Profile: The OAK Studyover 11 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















